Cisplatin and ZD1839 + Re-Irradiation in Recurrent Squamous Cell Cancer of the Head and Neck
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine safety profile of the epidermal growth factor receptor (EGFR) antagonist, ZD1839
in combination with cisplatin and radiation therapy in patients with local-regional recurrent
squamous cell cancer of the head and neck.
To study the effects of ZD1839 combined with either cisplatin or radiotherapy on signal
transduction pathway gene expression in tumor cells in patients with local-regional recurrent
squamous cell cancer of the head and neck using micro array analysis from tumor samples taken
at the time of relapse and during treatment.